LARGE CELL NEUROENDOCRINE CARCINOMA
Clinical trials for LARGE CELL NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LARGE CELL NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for LARGE CELL NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control Recruiting nowThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat cancers: first human trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called FZ-AD005 in people with advanced solid tumors, especially small cell lung cancer and large cell neuroendocrine carcinoma. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 162 partic…
Matched conditions: LARGE CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC